UM Ventures’ GlycoT Therapeutics grants technology sublicense to Daiichi Sankyo

GlycoT Therapeutics LLC, a UM Ventures startup company based on intellectual property developed at the University of Maryland, Baltimore and University of Maryland, College Park, executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited, GlycoT officials said Monday. The agreement grants Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB and UMCP, and includes ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *